{"data":[{"accessionNo":"0001193125-26-421651","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662774","issuerName":"IRulya Therapeutics Inc.","ticker":"QNCX","cusip":"22053A305","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-10-06","reportingPerson":"Joseph Edelman","reportingCik":null,"personType":"IN","sharesOwned":912853,"percentOfClass":8.4,"filedAt":"2026-10-14","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0001193125-26-421651","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662774","issuerName":"IRulya Therapeutics Inc.","ticker":"QNCX","cusip":"22053A305","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-10-06","reportingPerson":"Perceptive Advisors LLC","reportingCik":null,"personType":"IA","sharesOwned":912853,"percentOfClass":8.4,"filedAt":"2026-10-14","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0001193125-26-421651","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662774","issuerName":"IRulya Therapeutics Inc.","ticker":"QNCX","cusip":"22053A305","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-10-06","reportingPerson":"Perceptive Life Sciences Master Fund, Ltd.","reportingCik":null,"personType":"CO","sharesOwned":912853,"percentOfClass":8.4,"filedAt":"2026-10-14","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0001104659-26-115859","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662774","issuerName":"IRulya Therapeutics Inc.","ticker":"QNCX","cusip":"22053A305","securityClass":"Common Stock","eventDate":"2026-10-06","reportingPerson":"James B. Tananbaum","reportingCik":null,"personType":"IN","sharesOwned":652039,"percentOfClass":6,"filedAt":"2026-10-14","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0001104659-26-115859","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662774","issuerName":"IRulya Therapeutics Inc.","ticker":"QNCX","cusip":"22053A305","securityClass":"Common Stock","eventDate":"2026-10-06","reportingPerson":"Foresite Capital Management VI, LLC","reportingCik":null,"personType":"OO","sharesOwned":489029,"percentOfClass":4.5,"filedAt":"2026-10-14","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0001104659-26-115859","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662774","issuerName":"IRulya Therapeutics Inc.","ticker":"QNCX","cusip":"22053A305","securityClass":"Common Stock","eventDate":"2026-10-06","reportingPerson":"Foresite Capital Fund VI LP","reportingCik":null,"personType":"PN","sharesOwned":489029,"percentOfClass":4.5,"filedAt":"2026-10-14","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0001104659-26-115859","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662774","issuerName":"IRulya Therapeutics Inc.","ticker":"QNCX","cusip":"22053A305","securityClass":"Common Stock","eventDate":"2026-10-06","reportingPerson":"Foresite Public & Crossover Opportunities Management I, LLC","reportingCik":null,"personType":"OO","sharesOwned":163010,"percentOfClass":1.5,"filedAt":"2026-10-14","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0001104659-26-115859","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662774","issuerName":"IRulya Therapeutics Inc.","ticker":"QNCX","cusip":"22053A305","securityClass":"Common Stock","eventDate":"2026-10-06","reportingPerson":"Foresite Public & Crossover Opportunities Fund I, L.P.","reportingCik":null,"personType":"PN","sharesOwned":163010,"percentOfClass":1.5,"filedAt":"2026-10-14","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0001172661-26-003433","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662774","issuerName":"Quince Therapeutics, Inc.","ticker":"QNCX","cusip":"22053A305","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"BALYASNY ASSET MANAGEMENT L.P.","reportingCik":null,"personType":"IA,PN","sharesOwned":97699,"percentOfClass":9.99,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0001172661-26-003433","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662774","issuerName":"Quince Therapeutics, Inc.","ticker":"QNCX","cusip":"22053A305","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"BAM GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":97699,"percentOfClass":9.99,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0001172661-26-003433","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662774","issuerName":"Quince Therapeutics, Inc.","ticker":"QNCX","cusip":"22053A305","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"Balyasny Asset Management Holdings LP","reportingCik":null,"personType":"HC,PN","sharesOwned":97699,"percentOfClass":9.99,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0001172661-26-003433","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662774","issuerName":"Quince Therapeutics, Inc.","ticker":"QNCX","cusip":"22053A305","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"Dames GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":97699,"percentOfClass":9.99,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0001172661-26-003433","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662774","issuerName":"Quince Therapeutics, Inc.","ticker":"QNCX","cusip":"22053A305","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"Dmitry Balyasny","reportingCik":null,"personType":"HC,IN","sharesOwned":97699,"percentOfClass":9.99,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0001172661-26-003692","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662774","issuerName":"Quince Therapeutics, Inc.","ticker":"QNCX","cusip":"22053A305","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Cormorant Asset Management, LP","reportingCik":null,"personType":"IA,PN","sharesOwned":108029,"percentOfClass":9.99,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0001172661-26-003692","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662774","issuerName":"Quince Therapeutics, Inc.","ticker":"QNCX","cusip":"22053A305","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Bihua Chen","reportingCik":null,"personType":"HC,IN","sharesOwned":108029,"percentOfClass":9.99,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0001193125-26-352966","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662774","issuerName":"Quince Therapeutics, Inc.","ticker":"QNCX","cusip":"22053A305","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Neil Shahrestani","reportingCik":null,"personType":"IN,HC","sharesOwned":91789,"percentOfClass":9,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0001193125-26-352966","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662774","issuerName":"Quince Therapeutics, Inc.","ticker":"QNCX","cusip":"22053A305","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Ikarian Capital, LLC","reportingCik":null,"personType":"IA","sharesOwned":91789,"percentOfClass":9,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0001104659-26-097291","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001662774","issuerName":"QUINCE THERAPEUTICS, INC.","ticker":"QNCX","cusip":"22053A305","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Nantahala Capital Management, LLC","reportingCik":null,"personType":"IA","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0001104659-26-097291","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001662774","issuerName":"QUINCE THERAPEUTICS, INC.","ticker":"QNCX","cusip":"22053A305","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Wilmot B. Harkey","reportingCik":null,"personType":"HC","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0001104659-26-097291","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001662774","issuerName":"QUINCE THERAPEUTICS, INC.","ticker":"QNCX","cusip":"22053A305","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Daniel Mack","reportingCik":null,"personType":"HC","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0002050709-26-000021","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662774","issuerName":"Quince Therapeutics, Inc.","ticker":"QNCX","cusip":"22053A305","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-07-28","reportingPerson":"Squadron Master Fund LP","reportingCik":null,"personType":"PN","sharesOwned":55173,"percentOfClass":5.6,"filedAt":"2026-08-04","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0002050709-26-000021","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662774","issuerName":"Quince Therapeutics, Inc.","ticker":"QNCX","cusip":"22053A305","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-07-28","reportingPerson":"Squadron Capital Management LLC","reportingCik":null,"personType":"IA,HC","sharesOwned":55173,"percentOfClass":5.6,"filedAt":"2026-08-04","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0002050709-26-000021","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662774","issuerName":"Quince Therapeutics, Inc.","ticker":"QNCX","cusip":"22053A305","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-07-28","reportingPerson":"Matthew Sesterhenn","reportingCik":null,"personType":"HC,IN","sharesOwned":55173,"percentOfClass":5.6,"filedAt":"2026-08-04","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0002050709-26-000021","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662774","issuerName":"Quince Therapeutics, Inc.","ticker":"QNCX","cusip":"22053A305","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-07-28","reportingPerson":"William Blank","reportingCik":null,"personType":"HC,IN","sharesOwned":55173,"percentOfClass":5.6,"filedAt":"2026-08-04","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0001104659-26-072388","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662774","issuerName":"Quince Therapeutics, Inc.","ticker":"QNCX","cusip":"22053A206","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-04","reportingPerson":"Israel A. Englander","reportingCik":null,"personType":"IN","sharesOwned":1403697,"percentOfClass":7.2,"filedAt":"2026-06-10","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0001104659-26-072388","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662774","issuerName":"Quince Therapeutics, Inc.","ticker":"QNCX","cusip":"22053A206","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-04","reportingPerson":"Millennium Group Management LLC","reportingCik":null,"personType":"OO","sharesOwned":1403697,"percentOfClass":7.2,"filedAt":"2026-06-10","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0001104659-26-072388","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662774","issuerName":"Quince Therapeutics, Inc.","ticker":"QNCX","cusip":"22053A206","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-04","reportingPerson":"Millennium Management LLC","reportingCik":null,"personType":"OO","sharesOwned":1403697,"percentOfClass":7.2,"filedAt":"2026-06-10","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0001104659-26-072388","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662774","issuerName":"Quince Therapeutics, Inc.","ticker":"QNCX","cusip":"22053A206","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-04","reportingPerson":"Integrated Core Strategies (US) LLC","reportingCik":null,"personType":"OO","sharesOwned":1403580,"percentOfClass":7.2,"filedAt":"2026-06-10","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0001104659-26-062688","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001662774","issuerName":"QUINCE THERAPEUTICS, INC.","ticker":"QNCX","cusip":"22053A107","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Nantahala Capital Management, LLC","reportingCik":null,"personType":"IA","sharesOwned":4528302,"percentOfClass":7.52,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0001104659-26-062688","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001662774","issuerName":"QUINCE THERAPEUTICS, INC.","ticker":"QNCX","cusip":"22053A107","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Wilmot B. Harkey","reportingCik":null,"personType":"HC","sharesOwned":4528302,"percentOfClass":7.52,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0001104659-26-062688","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001662774","issuerName":"QUINCE THERAPEUTICS, INC.","ticker":"QNCX","cusip":"22053A107","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Daniel Mack","reportingCik":null,"personType":"HC","sharesOwned":4528302,"percentOfClass":7.52,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0000932540-26-000004","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662774","issuerName":"Quince Therapeutics, Inc.","ticker":"QNCX","cusip":null,"securityClass":"Common Stock, par value $0.0001 par value","eventDate":"2026-02-28","reportingPerson":"GROUP ONE TRADING LLC","reportingCik":null,"personType":"BD","sharesOwned":5942906,"percentOfClass":10.7,"filedAt":"2026-03-05","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0001104659-25-112623","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001662774","issuerName":"Quince Therapeutics, Inc.","ticker":"QNCX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-30","reportingPerson":"Nantahala Capital Management, LLC","reportingCik":null,"personType":"IA","sharesOwned":5620422,"percentOfClass":9.99,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0001104659-25-112623","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001662774","issuerName":"Quince Therapeutics, Inc.","ticker":"QNCX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-30","reportingPerson":"Wilmot B. Harkey","reportingCik":null,"personType":"HC","sharesOwned":5620422,"percentOfClass":9.99,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0001104659-25-112623","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001662774","issuerName":"Quince Therapeutics, Inc.","ticker":"QNCX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-30","reportingPerson":"Daniel Mack","reportingCik":null,"personType":"HC","sharesOwned":5620422,"percentOfClass":9.99,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0001140361-25-039832","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001662774","issuerName":"Quince Therapeutics, Inc.","ticker":"QNCX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-07-07","reportingPerson":"Genextra S.p.A.","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2025-10-30","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0001140361-25-039832","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001662774","issuerName":"Quince Therapeutics, Inc.","ticker":"QNCX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-07-07","reportingPerson":"Francesco Micheli","reportingCik":null,"personType":"IN","sharesOwned":0,"percentOfClass":0,"filedAt":"2025-10-30","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"},{"accessionNo":"0001140361-25-039832","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001662774","issuerName":"Quince Therapeutics, Inc.","ticker":"QNCX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-07-07","reportingPerson":"Matteo Bruno Renzulli","reportingCik":null,"personType":"IN","sharesOwned":0,"percentOfClass":0,"filedAt":"2025-10-30","canonicalUrl":"https://xoomar.com/markets/stocks/qncx"}],"updatedAt":"2026-11-05T11:56:53.814Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/qncx","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}